BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Discovery of 14-3-3 zeta as a potential biomarker for cardiac hypertrophy

  • Joyeta Mahmud (Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology) ;
  • Hien Thi My Ong (Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology) ;
  • Eda Ates (Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology) ;
  • Hong Seog Seo (Cardiovascular Center, Korea University Guro Hospital, Korea University Medicine) ;
  • Min-Jung Kang (Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology)
  • Received : 2022.11.24
  • Accepted : 2023.03.24
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Acute myocardial infarction (AMI) is a multifaceted syndrome influenced by the functions of various extrinsic and intrinsic pathways and pathological processes, which can be detected in circulation using biomarkers. In this study, we investigated the secretome protein profile of induced-hypertrophy cardiomyocytes to identify next-generation biomarkers for AMI diagnosis and management. Hypertrophy was successfully induced in immortalized human cardiomyocytes (T0445) by 200 nM ET-1 and 1 μM Ang II. The protein profiles of hypertrophied cardiomyocyte secretomes were analyzed by nano-liquid chromatography with tandem mass spectrometry and differentially expressed proteins that have been identified by Ingenuity Pathway Analysis. The levels of 32 proteins increased significantly (>1.4 fold), whereas 17 proteins (<0.5 fold) showed a rapid decrease in expression. Proteomic analysis showed significant upregulation of six 14-3-3 protein isoforms in hypertrophied cardiomyocytes compared to those in control cells. Multi-reaction monitoring results of human plasma samples showed that 14-3-3 protein-zeta levels were significantly elevated in patients with AMI compared to those of healthy controls. These findings elucidated the role of 14-3-3 protein-zeta in cardiac hypertrophy and cardiovascular disorders and demonstrated its potential as a novel biomarker and therapeutic strategy.

Keywords

Acknowledgement

This study was supported by the National Research Foundation of Korea (NRF) and funded by the Ministry of Science and ICT, Republic of Korea (no. NRF-2017R1A2B2004398, NRF-2021R1A2C209370611), and the Korea Institute of Science and Technology (KIST) Institutional Program (2E31623).

References

  1. Thrift AG, Thayabaranathan T, Howard G et al (2017) Global stroke statistics. Int J Stroke 12, 13-32  https://doi.org/10.1177/1747493016676285
  2. Maron BJ (2018) Clinical course and management of hypertrophic cardiomyopathy. NJEM 379, 655-668  https://doi.org/10.1056/NEJMra1710575
  3. Rowin EJ, Maron BJ and Maron MS (2020) The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications. Cardiovasc Imag 13, 2002-2016  https://doi.org/10.1016/j.jcmg.2019.09.020
  4. Laflamme MA and Murry CE (2011) Heart regeneration. Nature 473, 326-335  https://doi.org/10.1038/nature10147
  5. Garg P, Morris P, Fazlanie AL et al (2017) Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med 12, 147-155  https://doi.org/10.1007/s11739-017-1612-1
  6. Babuin L and Jaffe AS (2005) Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173, 1191-1202  https://doi.org/10.1503/cmaj/051291
  7. Mueller T, Gegenhuber A, Poelz W and Haltmayer M (2005) Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91, 606-612  https://doi.org/10.1136/hrt.2004.037762
  8. Toldo S and Abbate A (2018) The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 15, 203-214  https://doi.org/10.1038/nrcardio.2017.161
  9. Kang MJ, Seong Y, Mahmud J and Nguyen BT (2020) Obscurin and clusterin elevation in serum of acute myocardial infarction patients. Bull Korean Chem Soc 41, 266-273  https://doi.org/10.1002/bkcs.11955
  10. Chan D and Ng LL (2010) Biomarkers in acute myocardial infarction. BMC Med 8, 1-11  https://doi.org/10.1186/1741-7015-8-1
  11. Watkins SJ, Borthwick GM and Arthur HM (2011) The H9C2 cell line and primary neonatal cardio myocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47, 125-131  https://doi.org/10.1007/s11626-010-9368-1
  12. Manso AM, Li R, Monkley SJ et al (2013) Talin1 has unique expression versus talin 2 in the heart and modifies the hypertrophic response to pressure overload. J Biol Chem 288, 4252-4264  https://doi.org/10.1074/jbc.M112.427484
  13. Bandaru S, Ala C, Zhou AX and Akyurek LM (2021) Filamin A regulates cardiovascular remodeling. Int J Mol Sci 22, 6555 
  14. Lee SY, Kim DY, Kwak MK et al (2019) High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state. Endocr J 66, 241-251  https://doi.org/10.1507/endocrj.EJ18-0352
  15. Paszek E, Zmudka K, Plens K, Legutko J, Rajs T and Zajdel W (2020) Evaluation of profilin 1 as a biomarker in myocardial infarction. Eur Rev Med Pharmacol Sci 24, 8112-8116 
  16. Yang D, Wang Y, Jiang M et al (2017) Downregulation of profilin-1 expression attenuates cardiomyocytes hypertrophy and apoptosis induced by advanced glycation end products in H9c2 cells. Biomed Res Int 2017, 9716087 
  17. Klopsch C, Gaebel R, Lemcke H et al (2018) Vimentin-induced cardiac mesenchymal stem cells proliferate in the acute ischemic myocardium. Cells Tissues Organs 206, 35-45  https://doi.org/10.1159/000495527
  18. Gong DH, Dai Y, Chen S et al (2019) Secretory vimentin is associated with coronary artery disease in patients and induces atherogenesis in ApoE(-/-) mice. Int J Cardiol 283, 9-16  https://doi.org/10.1016/j.ijcard.2019.02.032
  19. Zhou X, Tian F, Sandzen J et al (2007) Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci USA 104, 3919-3924  https://doi.org/10.1073/pnas.0608360104
  20. Carrascosa JL, Llorca O and Valpuesta JM (2001) Structural comparison of prokaryotic and eukaryotic chaperonins. Micron 32, 43-50  https://doi.org/10.1016/S0968-4328(00)00027-5
  21. Li JY, Patterson M, Mikkola HK, Lowry WE and Kurdistani SK (2012) Dynamic distribution of linker histone H1.5 in cellular differentiation. PLoS Genet 8, e1002879 
  22. Bauden M, Kristl T, Sasor A et al (2017) Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. BMC Cancer 17, 810 
  23. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL and Hayoz D (2004) Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 61, 2614-2623  https://doi.org/10.1007/s00018-004-4225-6
  24. Severino V, Farina A and Chambery A (2013) Analysis of secreted proteins. Methods Mol Biol 1002, 37-60  https://doi.org/10.1007/978-1-62703-360-2_4
  25. Hernandez-Ruiz L, Valverde F, Jimenez-Nunez MD et al (2007) Organellar proteomics of human platelet dense granules reveals that 14-3-3ζ is a granule protein related to atherosclerosis. J Proteome Res 6, 4449-4457  https://doi.org/10.1021/pr070380o
  26. Thompson WC and Goldspink PH (2022) 14-3-3 protein regulation of excitation-contraction coupling. Pflug Arch Eur J Phy 474, 267-279  https://doi.org/10.1007/s00424-021-02635-x
  27. Mugabo Y, Zhao C, Tan JJ et al (2022) 14-3-3ζ Constrains insulin secretion by regulating mitochondrial function in pancreatic β cells. JCI insight 7, e156378 
  28. Zhou Q, Li L, Zhao B and Guan K (2015) The hippo pathway in heart development, regeneration, and diseases. Circ Res 116, 1431-1447  https://doi.org/10.1161/CIRCRESAHA.116.303311
  29. Zhou W and Zhao M (2018) How hippo signaling pathway modulates cardiovascular development and diseases. J Immuno Res 2018, 3696914 
  30. Seo J and Kim J (2018) Regulation of hippo signaling by actin remodeling. BMB Rep 51, 151-156 https://doi.org/10.5483/BMBRep.2018.51.3.012